Beam Therapeutics Inc. Payments to Acquire Debt Securities, Available-for-sale
Beam Therapeutics Inc. (BEAM) reported Payments to Acquire Debt Securities, Available-for-sale of $334.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $180.92M, a 45.82% decline year-over-year.
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $153.79M, a 54.66% decline year-over-year.
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $361.04M.
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $175.64M, a 12.07% increase year-over-year.
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.21B, a 148.70% increase from fiscal 2024.
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $486.44M, a 50.58% decline from fiscal 2023.
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $984.34M, a 39.13% decline from fiscal 2022.
- Beam Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $1.62B, a 108.05% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $180.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $334.71M 10-Q · filed 2026-08-04 | $695.75M derived: sum of 3 quarters · filed 2026-08-04 | $871.39M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $153.79M 10-Q · filed 2026-05-07 | $514.83M derived: sum of 2 quarters · filed 2026-05-07 | $690.47M derived: sum of 3 quarters · filed 2026-05-07 | $1.02B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $361.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $536.68M derived: sum of 2 quarters · filed 2026-02-24 | $870.62M derived: sum of 3 quarters · filed 2026-08-04 | $1.21B 10-K · filed 2026-02-24 |
| 2025-09-30 | $175.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $509.58M derived: sum of 2 quarters · filed 2026-08-04 | $848.75M 10-Q · filed 2025-11-04 | $848.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $333.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $673.11M 10-Q · filed 2026-08-04 | $673.11M derived: sum of 3 quarters · filed 2026-08-04 | $829.84M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $339.17M 10-Q · filed 2026-05-07 | $339.17M derived: sum of 2 quarters · filed 2026-05-07 | $495.89M derived: sum of 3 quarters · filed 2026-05-07 | $630.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $156.72M derived: sum of 2 quarters · filed 2026-02-24 | $291.20M derived: sum of 3 quarters · filed 2026-02-24 | $486.44M 10-K · filed 2026-02-24 |
| 2024-09-30 | $156.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $291.20M derived: sum of 2 quarters · filed 2025-11-04 | $486.44M 10-Q · filed 2025-11-04 | $539.71M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $134.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $329.71M 10-Q · filed 2025-08-05 | $382.99M derived: sum of 3 quarters · filed 2026-02-24 | $656.69M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $195.24M 10-Q · filed 2025-05-06 | $248.51M derived: sum of 2 quarters · filed 2026-02-24 | $522.22M derived: sum of 3 quarters · filed 2026-02-24 | $913.05M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $53.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $326.98M derived: sum of 2 quarters · filed 2026-02-24 | $717.81M derived: sum of 3 quarters · filed 2026-02-24 | $984.34M 10-K · filed 2026-02-24 |
| 2023-09-30 | $273.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $664.53M derived: sum of 2 quarters · filed 2024-11-05 | $931.07M 10-Q · filed 2024-11-05 | $1.17B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $390.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $657.36M 10-Q · filed 2024-08-06 | $895.75M derived: sum of 3 quarters · filed 2025-02-25 | $1.25B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $266.53M 10-Q · filed 2024-05-07 | $504.92M derived: sum of 2 quarters · filed 2025-02-25 | $862.95M derived: sum of 3 quarters · filed 2025-02-25 | $1.19B derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $238.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $596.42M derived: sum of 2 quarters · filed 2025-02-25 | $926.61M derived: sum of 3 quarters · filed 2025-02-25 | $1.62B 10-K · filed 2025-02-25 |
| 2022-09-30 | $358.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $688.22M derived: sum of 2 quarters · filed 2023-11-08 | $1.38B 10-Q · filed 2023-11-08 | $1.55B derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $330.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.02B 10-Q · filed 2023-08-08 | $1.19B derived: sum of 3 quarters · filed 2024-02-27 | $1.37B derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $690.39M 10-Q · filed 2023-05-10 | $860.87M derived: sum of 2 quarters · filed 2024-02-27 | $1.04B derived: sum of 3 quarters · filed 2024-02-27 | $1.18B derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $170.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $348.98M derived: sum of 2 quarters · filed 2024-02-27 | $488.00M derived: sum of 3 quarters · filed 2024-02-27 | $777.22M 10-K · filed 2024-02-27 |
| 2021-09-30 | $178.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $317.53M derived: sum of 2 quarters · filed 2022-11-07 | $606.75M 10-Q · filed 2022-11-07 | $721.26M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $139.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $428.25M 10-Q · filed 2022-08-09 | $542.76M derived: sum of 3 quarters · filed 2023-02-28 | $573.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $289.22M 10-Q · filed 2022-05-09 | $403.74M derived: sum of 2 quarters · filed 2023-02-28 | $434.87M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $114.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $145.65M derived: sum of 2 quarters · filed 2023-02-28 | $281.61M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $31.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $167.09M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $135.96M 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | $129.76M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |